Document 0845
 DOCN  M95A0845
 TI    Prospects for immunotoxin therapy of non-Hodgkin's lymphoma.
 DT    9510
 AU    Grossbard ML; Fidias P; Hematology/Oncology Unit, Massachusetts General
       Hospital, Boston; 02114, USA.
 SO    Clin Immunol Immunopathol. 1995 Aug;76(2):107-14. Unique Identifier :
       AIDSLINE MED/95339601
 AB    The use of unconjugated monoclonal antibodies to treat patients with
       non-Hodgkin's lymphoma by targeting specific antigenic determinants on
       malignant cells has been an area of intense laboratory and clinical
       research. Although occasional clinical successes have been seen, many
       limitations of such therapy have been identified, including the low
       endogenous cytotoxicity of most of the antibodies. More recently,
       investigators have attempted to employ monoclonal antibody-toxin
       conjugates (immunotoxins) to deliver specific cytotoxins to the lymphoma
       cell surface. This article describes the preclinical development of
       immunotoxin therapy as well as the initial results from selected Phase I
       and II clinical trials in patients with NHL. In addition, future
       directions are suggested for the use of these agents as adjuvant therapy
       and as treatment for patients with human immunodeficiency virus-related
       NHL.
 DE    Adjuvants, Immunologic/THERAPEUTIC USE  Antibodies,
       Monoclonal/THERAPEUTIC USE  Human  Immunotherapy/TRENDS
       Immunotoxins/ADVERSE EFFECTS/*THERAPEUTIC USE  Lymphoma,
       Non-Hodgkin's/*THERAPY  Ricin/THERAPEUTIC USE  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).